Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Claudin-3 and Claudin-4 Distinct Prognostic Significance in Triple-Negative and Luminal Breast Cancer

Claudin-3 and Claudin-4 Distinct Prognostic Significance in Triple-Negative and Luminal Breast... RESEARCH ARTICLE Claudin-3 and Claudin-4: Distinct Prognostic Significance in Triple-Negative and Luminal Breast Cancer Panagiota Kolokytha, MD,* Petros Yiannou, MD,w Dimitris Keramopoulos, MD,z Argyrios Kolokythas, MS-V,y Afroditi Nonni, MD, PhD,* Efstratios Patsouris, MD, PhD,* and Kitty Pavlakis, MD, PhD* espite the important decrease of breast cancer mor- Introduction: To investigate the immunohistochemical ex- Dtality, apparently as a result of screening/prevention pression of claudin-1, claudin-3, and claudin-4 in triple-negative programs and the appliance of new therapeutic strategies, breast carcinomas and compare it with several clinicopathologic a great percentage of women with breast cancer will still parameters as well as their expression in luminal cancers. 1 succumb from their disease. The above epidemiological fact might in part be related to the biological hetero- Materials and Methods: A total of 128 cases of breast carcinoma geneity that characterizes breast carcinoma. Tradition- were included in the study. For all these cases, immuno- ally, several clinical and pathologic parameters have been histochemistry for estrogen and progesterone receptors, Ki-67, used to classify breast cancer into relative distinct groups and Her2 had already been performed, whereas Her2 2+ cases with different malignant potential needing discrete ther- had been further characterized as positive or negative for Her2 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Claudin-3 and Claudin-4 Distinct Prognostic Significance in Triple-Negative and Luminal Breast Cancer

Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/claudin-3-and-claudin-4-distinct-prognostic-significance-in-triple-Q0NSNWszRT

References (25)

Copyright
Copyright © 2013 by Lippincott Williams & Wilkins
ISSN
1541-2016
DOI
10.1097/PAI.0b013e31828d9d62
pmid
23702644
Publisher site
See Article on Publisher Site

Abstract

RESEARCH ARTICLE Claudin-3 and Claudin-4: Distinct Prognostic Significance in Triple-Negative and Luminal Breast Cancer Panagiota Kolokytha, MD,* Petros Yiannou, MD,w Dimitris Keramopoulos, MD,z Argyrios Kolokythas, MS-V,y Afroditi Nonni, MD, PhD,* Efstratios Patsouris, MD, PhD,* and Kitty Pavlakis, MD, PhD* espite the important decrease of breast cancer mor- Introduction: To investigate the immunohistochemical ex- Dtality, apparently as a result of screening/prevention pression of claudin-1, claudin-3, and claudin-4 in triple-negative programs and the appliance of new therapeutic strategies, breast carcinomas and compare it with several clinicopathologic a great percentage of women with breast cancer will still parameters as well as their expression in luminal cancers. 1 succumb from their disease. The above epidemiological fact might in part be related to the biological hetero- Materials and Methods: A total of 128 cases of breast carcinoma geneity that characterizes breast carcinoma. Tradition- were included in the study. For all these cases, immuno- ally, several clinical and pathologic parameters have been histochemistry for estrogen and progesterone receptors, Ki-67, used to classify breast cancer into relative distinct groups and Her2 had already been performed, whereas Her2 2+ cases with different malignant potential needing discrete ther- had been further characterized as positive or negative for Her2

Journal

Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health

Published: Feb 1, 2014

There are no references for this article.